Categories
  Encyclosphere.org ENCYCLOREADER
  supported by EncyclosphereKSF

Dual amylin and calcitonin receptor agonists

From Wikipedia - Reading time: 4 min

Dual amylin and calcitonin receptor agonists (DACRAs) are a class of drugs that act as agonists at the amylin receptor and calcitonin receptor that are under development as therapies for obesity and type 2 diabetes. Examples are cagrilintide and the KBP family derived from salmon calcitonin,[1] including KBP‐042,[2] KBP-066A,[3] KBP-089,[4] and KBP-336.[5]

References

[edit]
  1. ^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, M. A.; Henriksen, K. (December 2022). "Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 1950-6007. PMID 36242844.
  2. ^ Henriksen, Kim; Broekhuizen, Karen; de Boon, Wadim M. I.; Karsdal, Morten A.; Bihlet, Asger R.; Christiansen, Claus; Dillingh, Marlous R.; de Kam, Marieke; Kumar, Raj; Burggraaf, Jacobus; Kamerling, Ingrid M. C. (December 2021). "Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects". British Journal of Clinical Pharmacology. 87 (12): 4786–4796. doi:10.1111/bcp.14921. ISSN 0306-5251. S2CID 235093884.
  3. ^ Andreassen, K. V.; Larsen, A. T.; Sonne, N.; Mohamed, K. E.; Karsdal, M. A.; Henriksen, K. (1 November 2021). "KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats". Molecular Metabolism. 53: 101282. doi:10.1016/j.molmet.2021.101282. ISSN 2212-8778. PMC 8313742. PMID 34214708.
  4. ^ Larsen, Anna Thorsø; Gydesen, Sofie; Sonne, Nina; Karsdal, Morten Asser; Henriksen, Kim (7 January 2021). "The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile". BMC Endocrine Disorders. 21 (1): 10. doi:10.1186/s12902-020-00678-2. ISSN 1472-6823. PMC 7791885. PMID 33413317.
  5. ^ Melander, Simone A.; Larsen, Anna T.; Elhady Mohamed, Khaled; Karsdal, Morten A.; Henriksen, Kim (20 June 2023). "840-P: Dual Amylin and Calcitonin Receptor Agonist Treatment Improves Blood Pressure and Glucose Control in ZSF1 Rats". Diabetes. 72 (Supplement_1). doi:10.2337/db23-840-P. S2CID 259415731.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Licensed under CC BY-SA 3.0 | Source: https://en.wikipedia.org/wiki/Dual_amylin_and_calcitonin_receptor_agonists
1 |
↧ Download as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF